DSIP and insomnia: a small study with limited effects
Study model: Humans; double-blind study, 16 participants
The research question
A sleep peptide sounds promising, but what do people notice from it? A double-blind study in chronic insomnia shows why measurable changes and noticeable improvement should be considered separately.
What was found?
Researchers compared DSIP with placebo during consecutive nights in a sleep laboratory. They recorded sleep and asked participants about sleep quality and fatigue. Some objective measures, including sleep efficiency and sleep onset latency, were more favorable with DSIP. The effects were weak and may have been partly related to changes in the placebo group. Perceived sleep quality did not improve.
What does this evidence mean?
The authors saw little reason to expect a substantial therapeutic benefit from this short treatment. The small number of participants and the short observation period limit the conclusions. This study does not support the claim that DSIP resolves chronic insomnia.
Primary source
Research information, not treatment advice. The described study does not establish the safe use of an investigational product. Image: AI illustration, not a participant or a photograph from the study.
Related research products
View product specifications and available batch documentation. The studies discussed were not conducted with Peptidera products and do not prove the efficacy of our products. For laboratory research only; not for human or animal consumption.